FXYD3 Antibody (B-8): sc-271628

FXYD3 Antibody (B-8) is a mouse monoclonal IgG1 antibody that detects FXYD3 in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). FXYD3 is a member of the FXYD family, which plays a crucial role in maintaining sodium and potassium gradients across cell membranes, essential for various physiological processes including renal sodium reabsorption, muscle contraction, and neuronal excitability. This 67 amino acid protein is particularly interesting due to its potential function as a chloride channel or regulator, which is vital for cellular ion homeostasis and signaling. FXYD3 is expressed in a subset of human breast tumors, indicating its possible involvement in cancer biology, and shares partial homology with FXYD1, suggesting functional similarities. FXYD3 features a putative 20 amino acid leader sequence and a transmembrane domain that includes two cysteine residues, which may be important for structural integrity and function. Notably, FXYD3 lacks consensus phosphorylation sites in its cytoplasmic domain, which could influence regulatory mechanisms and interactions with other proteins. Anti-FXYD3 antibody (B-8) is an invaluable tool for researchers investigating the role of FXYD3 in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FXYD3 Antibody (B-8) References:

1. Expression and clinical significance of FXYD3 in endometrial cancer.  |  Li, Y., et al. 2014. Oncol Lett. 8: 517-522. PMID: 25013464
2. Prognostic significance of sodium-potassium ATPase regulator, FXYD3, in human hepatocellular carcinoma.  |  Wang, LJ., et al. 2018. Oncol Lett. 15: 3024-3030. PMID: 29435033
3. SOX9/FXYD3/Src Axis Is Critical for ER+ Breast Cancer Stem Cell Function.  |  Xue, Y., et al. 2019. Mol Cancer Res. 17: 238-249. PMID: 30206184
4. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.  |  Ma, YS., et al. 2021. J Cell Mol Med. 25: 4040-4052. PMID: 33621431
5. FXYD3 Expression Predicts Poor Prognosis in Renal Cell Carcinoma with Immunosuppressive Tumor Microenvironment.  |  Yonekura, S. and Ueda, K. 2022. Cancers (Basel). 14: PMID: 35892856
6. FXYD3 facilitates Na+ and liquid absorption across human airway epithelia by increasing the transport capacity of the Na/K ATPase.  |  Cano Portillo, C., et al. 2022. Am J Physiol Cell Physiol. 323: C1044-C1051. PMID: 35993520
7. FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes.  |  Yang, W., et al. 2023. Cell Mol Immunol. 20: 292-304. PMID: 36693922
8. FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.  |  Li, M., et al. 2023. J Clin Invest. 133: PMID: 37966117
9. Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer.  |  Yee, KX., et al. 2024. Am J Cancer Res. 14: 4353-4366. PMID: 39417182
10. FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival.  |  Rasko, NB., et al. 2025. Cancer Med. 14: e70500. PMID: 39783776

The preferred FXYD3 antibody is FXYD3 Antibody (A-8): sc-271808.